1. A STAT3-STING-IFN axis controls the metastatic spread of small cell lung cancer.
- Author
-
Guanizo AC, Luong Q, Jayasekara WSN, de Geus ED, Inampudi C, Xue VS, Chen J, de Weerd NA, Matthews AY, Gantier MP, Balic JJ, Arulananda S, Garama DJ, Hertzog PJ, Ganju V, Watkins DN, Cain JE, and Gough DJ
- Subjects
- Animals, Mice, Humans, Interferon Type I metabolism, Neoplasm Metastasis, Cell Line, Tumor, Mice, Knockout, Mice, Inbred C57BL, Immunity, Innate, Tumor Escape, Lung Neoplasms secondary, Lung Neoplasms immunology, Lung Neoplasms genetics, Lung Neoplasms pathology, STAT3 Transcription Factor metabolism, STAT3 Transcription Factor genetics, Small Cell Lung Carcinoma genetics, Small Cell Lung Carcinoma pathology, Small Cell Lung Carcinoma immunology, Small Cell Lung Carcinoma metabolism, Signal Transduction, Membrane Proteins metabolism, Membrane Proteins genetics
- Abstract
Small cell lung cancer (SCLC) is an aggressive neuroendocrine tumor characterized by a high metastatic potential with an overall survival rate of ~5%. The transcription factor signal transducer and activator of transcription 3 (STAT3) is overexpressed by >50% of tumors, including SCLC, but its role in SCLC development and metastasis is unclear. Here, we show that, while STAT3 deletion restricts primary tumor growth, it paradoxically enhances metastatic spread by promoting immune evasion. This occurs because STAT3 is crucial for maintaining the immune sensor stimulator of interferon (IFN) genes (STING). Without STAT3, the cyclic adenosine monophosphate-guanosine monophosphate synthase-STING pathway is inactive, resulting in decreased type I IFN secretion and an IFN gene signature. Importantly, restoration of IFN signaling through re-expression of endogenous STING, enforced expression of IFN response factor 7 or administration of recombinant type I IFN re-established antitumor immunity, inhibiting metastatic SCLC in vivo. These data show the potential of augmenting the innate immune response to block metastatic SCLC., Competing Interests: Competing interests: The authors declare no competing interests., (© 2024. The Author(s), under exclusive licence to Springer Nature America, Inc.)
- Published
- 2024
- Full Text
- View/download PDF